ReviewActa pharmacologica Sinica2022
Dezocine as a potent analgesic: overview of its pharmacological characterization.
Review in Acta pharmacologica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Different interventions in preventing sufentanil-induced cough: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Trial
- Dezocine as preemptive analgesia alleviates ultrapulse COJournal of cosmetic dermatology · 2024Trial
- Intraoperative Esketamine Is Effective at Reducing Acute Postoperative Pain in Bariatric Surgery Patients: a Randomized Control Trial.Obesity surgery · 2023Trial
- The Effect of Dezocine on the Median Effective Dose of Sufentanil-Induced Respiratory Depression in Patients Undergoing Spinal Anesthesia Combined with Low-Dose Dexmedetomidine.Drug design, development and therapy · 2023Trial
- Trial
- Article
- Mechanistic insights into ligand selectivity inActa pharmaceutica Sinica. B · 2026Article
- Patient satisfaction with postoperative analgesia after hepatobiliary and pancreatic surgery: a retrospective analysis.Frontiers in surgery · 2026Article
- Effect of Dezocine and Dexmedetomidine as Adjuvants in Ropivacaine for Incision Subcutaneous Infiltration Anesthesia on Incision Healing in Diabetic Rats.Brain and behavior · 2025Article
- Dexmedetomidine and dezocine targets (NR1H3 and ADRB1) are potential prognostic biomarkers for breast cancer.Discover oncology · 2025Article
- Comparison of dezocine and hydromorphone in post-cesarean epidural analgesia: a retrospective study.BMC anesthesiology · 2025Article
- Anacyphrethines A and B as potent analgesics: Multiple ion channel inhibitors with an unprecedented chemical architecture.Acta pharmaceutica Sinica. B · 2025Article
- Opioid analgesics for sedation-based gastrointestinal endoscopy.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Dezocine and Addiction: Friend or Foe?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparison of postoperative analgesia between dezocine plus flurbiprofen axetil and sufentanil in patients with CRC undergoing tumor resection: A prospective, observational study.Oncology letters · 2025Article
- Application and safety analysis of paravertebral block with dezocine and ropivacaine in video-assisted thoracoscopic surgery for lung cancer.Frontiers in medicine · 2025Article
- Dezocine Exerts Analgesic Effects in Chronic Pain by Activation of κ- and μ-Opioid Receptors and Inhibition of Norepinephrine and Serotonin Reuptake.Pain research & management · 2025Article
- Sufentanil-Dezocine Combination in Patient-Controlled Intravenous Analgesia for Postoperative Pain After Pancreatic Cancer Surgery: A Retrospective Propensity Score-Matched Study.Journal of pain research · 2025Article
- Effects of dezocine with ropivacaine on epidural analgesia during labor: a randomized controlled trial.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dezocine, a synthetic opioid, introduced in 1970s as an analgesic, was redeveloped for relieving moderate to severe pain by Yangtze River Pharmaceutical Group in China in 2009. To date, dezocine occupies 45% of China's opioid analgesic market. Along with dezocine being a dominated painkiller, a certain amount of research was conducted to elucidate dezocine's action. In this review we summarize the current knowledge on the receptor, preclinical and clinical pharmacology of dezocine. Briefly, preclinical data show that dezocine is effective under varying pain conditions, particularly chronic neuropathic pain and cancer pain, through activation of opioid receptors, and inhibition of norepinephrine reuptake. Clinical data establish the effectiveness of dezocine either as a primary analgesic for postoperative pain management or a supplement for balanced analgesia. The receptor profile of dezocine is different from known pure μ agonists, and allows it to be used in combination with other opioids for additivity in efficacy or lower incidence of adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.